Freeline’s early Gaucher disease data; Shorla raises $35M; Regenxbio to start pivotal DMD trial next year
Freeline’s early data on gene therapy for Gaucher disease: Freeline Therapeutics said Wednesday that its gene therapy for Gaucher disease looked …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
